Tarmo K.
- Country
- Sweden
- Department
- Psykiatrisk öppen-/slutenvård
Research Overview
Data & Insights
Has run more than one trial at 0 of 4 partner sites.
Specializations
Cardiovascular & Renal Medicine
Investigator advances therapeutic approaches for heart failure, atrial fibrillation and advanced chronic kidney disease, aiming to lower cardiovascular mortality and slow renal decline.
- Heart failure with preserved ejection fraction
- Atrial fibrillation in dialysis patients
- SGLT2‑inhibitor combination therapy
Work integrates anticoagulation strategies, neurohormonal modulation, and renal‑protective agents.
Oncology & Cancer Therapeutics
Focus lies on innovative treatments for solid tumours such as colorectal cancer, prostate cancer, and triple‑negative breast cancer, as well as rare malignancies like glioblastoma and cutaneous malignant melanoma.
- Adjuvant immunotherapy in melanoma
- Targeted chemotherapy augmentation
- Biomarker‑driven therapy selection
Research emphasizes precision medicine, combination regimens, and long‑term survival outcomes.
Neurology & Neuroimmunology
Investigator addresses neurodegenerative and neuroimmune disorders including multiple sclerosis, glioblastoma, generalized myasthenia gravis, and schizophrenia spectrum disorder, exploring disease‑modifying and immunomodulatory interventions.
- Ocrelizumab efficacy in multiple sclerosis
- Rituximab for psychotic disorders
- Cladribine in myasthenia gravis
Efforts target immune pathway modulation and neuroprotective outcomes.
Infectious Diseases & Immunization
Research encompasses antimicrobial strategies for multidrug‑resistant urinary tract infections, vaccine‑related immunity against HPV, measles and varicella‑zoster, and antiviral assessment in tick‑borne encephalitis.
- Alternative antibiotics for ESBL‑producing pathogens
- HPV vaccination coupled with screening
- Remdesivir efficacy in tick‑borne encephalitis
Studies aim to improve treatment safety, reduce resistance, and enhance vaccine‑induced protection.
Metabolic & Endocrine Disorders
Investigator contributes to management of type 1 diabetes, type 2 diabetes, and related metabolic complications, evaluating agents that affect insulin secretion, glucose control, and cardiovascular risk.
- Insulin secretion enhancement in new‑onset type 1 diabetes
- SGLT2‑inhibitor versus metformin in early type 2 diabetes
- Metformin impact on abdominal aortic aneurysm growth
Work focuses on preserving pancreatic function, reducing cardiovascular events, and addressing comorbid vascular pathology.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.